Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM (2019년 1월 3일). “Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia”. 《New England Journal of Medicine》 380: 11–22. doi:10.1056/NEJMoa1812792.
Vazhappilly R, Chen F (1998). “Eicosapentaenoic acid and docosahexaenoic acid production potential of microalgae and their heterotrophic growth”. 《Journal of the American Oil Chemists' Society》 75 (3): 393–397. doi:10.1007/s11746-998-0057-0.
Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, La Forge R, Daniels SR, Wilson DP, Morris PB, Wild RA, Grundy SM, Daviglus M, Ferdinand KC, Vijayaraghavan K, Deedwania PC, Aberg JA, Liao KP, McKenney JM, Ross JL, Braun LT, Ito MK, Bays HE, Brown WV, Underberg JA (2015). “National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2”. 《Journal of Clinical Lipidology》 9 (6 Suppl): S1–122.e1. doi:10.1016/j.jacl.2015.09.002. PMID26699442.
Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, La Forge R, Daniels SR, Wilson DP, Morris PB, Wild RA, Grundy SM, Daviglus M, Ferdinand KC, Vijayaraghavan K, Deedwania PC, Aberg JA, Liao KP, McKenney JM, Ross JL, Braun LT, Ito MK, Bays HE, Brown WV, Underberg JA (2015). “National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2”. 《Journal of Clinical Lipidology》 9 (6 Suppl): S1–122.e1. doi:10.1016/j.jacl.2015.09.002. PMID26699442.